vs
Side-by-side financial comparison of Broadway Financial Corp (BYFC) and CytomX Therapeutics, Inc. (CTMX). Click either name above to swap in a different company.
CytomX Therapeutics, Inc. is the larger business by last-quarter revenue ($18.7M vs $9.4M, roughly 2.0× Broadway Financial Corp). Broadway Financial Corp runs the higher net margin — 1934.0% vs -0.8%, a 1934.8% gap on every dollar of revenue. On growth, Broadway Financial Corp posted the faster year-over-year revenue change (10.1% vs -25.7%). Broadway Financial Corp produced more free cash flow last quarter ($-13.0K vs $-15.8M). Over the past eight quarters, Broadway Financial Corp's revenue compounded faster (9.7% CAGR vs -15.9%).
Virtu Financial, Inc. is an American high-frequency trading company. The company went public on the Nasdaq in 2015.
CytomX Therapeutics is a clinical-stage biotechnology company specializing in innovative cancer immunotherapies. It leverages its proprietary Probody technology platform to develop targeted therapies that activate exclusively in tumor microenvironments, minimizing off-target toxicities, with a pipeline covering multiple solid tumor indications and partnerships with leading global pharmaceutical firms.
BYFC vs CTMX — Head-to-Head
Income Statement — Q4 FY2025 vs Q2 FY2025
| Metric | | |
|---|---|---|
| Revenue | $9.4M | $18.7M |
| Net Profit | $1.0M | $-154.0K |
| Gross Margin | — | — |
| Operating Margin | — | -6.9% |
| Net Margin | 1934.0% | -0.8% |
| Revenue YoY | 10.1% | -25.7% |
| Net Profit YoY | -21.8% | 97.6% |
| EPS (diluted) | $0.02 | — |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $9.4M | — | ||
| Q3 25 | $9.0M | — | ||
| Q2 25 | $8.1M | $18.7M | ||
| Q1 25 | $8.3M | $50.9M | ||
| Q4 24 | $8.6M | $38.1M | ||
| Q3 24 | $8.7M | $33.4M | ||
| Q2 24 | $8.2M | $25.1M | ||
| Q1 24 | $7.8M | $41.5M |
| Q4 25 | $1.0M | — | ||
| Q3 25 | $-23.9M | — | ||
| Q2 25 | $752.0K | $-154.0K | ||
| Q1 25 | $-2.7M | $23.5M | ||
| Q4 24 | $1.3M | $18.9M | ||
| Q3 24 | $516.0K | $5.7M | ||
| Q2 24 | $256.0K | $-6.5M | ||
| Q1 24 | $-154.0K | $13.8M |
| Q4 25 | — | — | ||
| Q3 25 | -256.2% | — | ||
| Q2 25 | 12.8% | -6.9% | ||
| Q1 25 | -45.3% | 44.4% | ||
| Q4 24 | 21.7% | 46.4% | ||
| Q3 24 | 8.5% | 12.3% | ||
| Q2 24 | 4.8% | -33.7% | ||
| Q1 24 | -2.9% | 28.1% |
| Q4 25 | 1934.0% | — | ||
| Q3 25 | -264.2% | — | ||
| Q2 25 | 9.3% | -0.8% | ||
| Q1 25 | -32.3% | 46.2% | ||
| Q4 24 | 15.3% | 49.6% | ||
| Q3 24 | 5.9% | 17.2% | ||
| Q2 24 | 3.1% | -26.0% | ||
| Q1 24 | -2.0% | 33.3% |
| Q4 25 | $0.02 | — | ||
| Q3 25 | $-2.86 | — | ||
| Q2 25 | $0.00 | — | ||
| Q1 25 | $-0.39 | — | ||
| Q4 24 | $0.07 | — | ||
| Q3 24 | $-0.03 | — | ||
| Q2 24 | $0.02 | — | ||
| Q1 24 | $-0.02 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $10.5M | $49.0M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $262.8M | $119.9M |
| Total Assets | $1.3B | $175.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $10.5M | — | ||
| Q3 25 | $19.7M | — | ||
| Q2 25 | $29.5M | $49.0M | ||
| Q1 25 | $15.8M | $47.6M | ||
| Q4 24 | $61.4M | $38.1M | ||
| Q3 24 | $97.1M | $40.6M | ||
| Q2 24 | $89.8M | $43.2M | ||
| Q1 24 | $67.1M | $36.2M |
| Q4 25 | $262.8M | — | ||
| Q3 25 | $261.7M | — | ||
| Q2 25 | $284.7M | $119.9M | ||
| Q1 25 | $283.6M | $25.0M | ||
| Q4 24 | $285.0M | $-456.0K | ||
| Q3 24 | $286.2M | $-23.5M | ||
| Q2 24 | $282.1M | $-31.2M | ||
| Q1 24 | $281.1M | $-31.7M |
| Q4 25 | $1.3B | — | ||
| Q3 25 | $1.3B | — | ||
| Q2 25 | $1.2B | $175.1M | ||
| Q1 25 | $1.3B | $98.5M | ||
| Q4 24 | $1.3B | $120.5M | ||
| Q3 24 | $1.4B | $139.0M | ||
| Q2 24 | $1.4B | $159.2M | ||
| Q1 24 | $1.4B | $184.7M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $230.0K | $-15.8M |
| Free Cash FlowOCF − Capex | $-13.0K | $-15.8M |
| FCF MarginFCF / Revenue | -0.1% | -84.6% |
| Capex IntensityCapex / Revenue | 2.6% | 0.1% |
| Cash ConversionOCF / Net Profit | 0.22× | — |
| TTM Free Cash FlowTrailing 4 quarters | $2.3M | $-77.7M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $230.0K | — | ||
| Q3 25 | $3.8M | — | ||
| Q2 25 | $3.0M | $-15.8M | ||
| Q1 25 | $-4.3M | $-21.0M | ||
| Q4 24 | $1.4M | $-19.9M | ||
| Q3 24 | $6.1M | $-20.7M | ||
| Q2 24 | $9.8M | $-19.5M | ||
| Q1 24 | $-11.7M | $-26.0M |
| Q4 25 | $-13.0K | — | ||
| Q3 25 | $3.7M | — | ||
| Q2 25 | $3.0M | $-15.8M | ||
| Q1 25 | $-4.4M | $-21.2M | ||
| Q4 24 | $1.3M | $-20.0M | ||
| Q3 24 | $6.1M | $-20.7M | ||
| Q2 24 | $9.7M | $-19.6M | ||
| Q1 24 | $-11.7M | $-26.2M |
| Q4 25 | -0.1% | — | ||
| Q3 25 | 41.1% | — | ||
| Q2 25 | 37.0% | -84.6% | ||
| Q1 25 | -52.4% | -41.6% | ||
| Q4 24 | 14.7% | -52.5% | ||
| Q3 24 | 69.6% | -62.1% | ||
| Q2 24 | 118.9% | -78.2% | ||
| Q1 24 | -149.7% | -63.1% |
| Q4 25 | 2.6% | — | ||
| Q3 25 | 1.2% | — | ||
| Q2 25 | 0.2% | 0.1% | ||
| Q1 25 | 0.2% | 0.2% | ||
| Q4 24 | 1.6% | 0.2% | ||
| Q3 24 | 0.3% | 0.1% | ||
| Q2 24 | 0.5% | 0.4% | ||
| Q1 24 | 0.7% | 0.3% |
| Q4 25 | 0.22× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | 4.00× | — | ||
| Q1 25 | — | -0.89× | ||
| Q4 24 | 1.06× | -1.05× | ||
| Q3 24 | 11.85× | -3.61× | ||
| Q2 24 | 38.21× | — | ||
| Q1 24 | — | -1.89× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BYFC
Segment breakdown not available.
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
